Zealand Pharma executed transactions to buy back 170,000 shares during week 27 (June 29 - July 3, 2026) as part of its ongoing share buy-back program. The company has repurchased a total of 1,619,000 shares worth approximately DKK 487.7 million since the program began on May 7, 2026, with a maximum limit of DKK 1.3 billion. Following these transactions, Zealand Pharma holds 2,489,482 treasury shares, representing about 3.47% of its total share capital. The buy-back program is set to complete by October 31, 2026, aiming to optimize shareholder value.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
